D
introduction of AIS systems in hydrocephalic patient populations has led to a decreased incidence of early shunt infection, that is, those occurring less than 6 months postinsertions. 9, 13 However, a reluctance to use such systems still exists because of their increased costs in comparison with standard shunt components. In the present clinical study, the primary objective was to determine the factors contributing to the medical costs of shunt infection treatment in a hydrocephalic pediatric population receiving standard components compared with those receiving antibiotic-impregnated CSF shunt components.
CLINICAL MATERIAL AND METHODS
Data in all pediatric patients who had undergone CSF shunt insertion at the Johns Hopkins Hospital over a 3-year period between April 2001 and March 2004 were retrospectively reviewed. Patient demographics, CSF shunting history, clinical presentation, radiological studies, operative variables, and shunt type and configuration were reviewed in all cases. During the 18 months prior to October 2002, more than 90% of CSF shunts (ventriculoperitoneal, ventriculoatrial, and ventriculopleural) included a standard nonimpregnated shunt catheter attached to one of various programmable and nonprogrammable shunt valve designs. During the 18 months following October 2002, the CSF shunts consisted of either a medium-pressure unishunt system impregnated with clindamycin and rifampin (Bactiseal, Codman, Johnson & Johnson), or an antibiotic-impregnated ventricular or distal catheter to the existing shunt system in cases in which only a proximal or distal shunt revision was indicated, respectively.
All patients were followed up for 12 months after shunt surgery. Shunt-related complications and the date and origin of shunt failure were recorded. Patients with shunt infection were defined as those clinically suspected of having an infection (fever, increased white blood cells, and/or wound breakdown involving the shunt) with positive cultures of CSF and/or hardware. For intercohort comparisons, parametric data were compared using a twoway analysis of variance. Nonparametric data were compared using a Mann-Whitney U-test. Percentages were compared with chi-square tests. The independent association between AIS catheter use and subsequent shunt infection was assessed with a multivariate proportional-hazards regression analysis (Statview, SAS), adjusting for all intercohort covariate differences (p Ͻ 0.01). Whether the shunt placement was a primary procedure or a revision was also adjusted for in the multivariate model. Factors contributing to increased medical costs were recorded and included the duration of hospital stay, inpatient complications related to infection treatment, long-term complications, multiple organism infections, and number of patients requiring multiple antibiotic regimens.
RESULTS

Patient Population
Three hundred fifty-three shunting procedures were performed for hydrocephalus in pediatric patients at the Johns Hopkins Hospital between April 2001 and April 2004. One hundred ninety-five of these operations (55%) were performed in male patients, and 158 (45%) in female patients. The age range of these patients was 1 to 16 years. The origin of hydrocephalus was related to a congenital abnormality in 97 (27%), intracranial hemorrhage in 88 (25%), myelodysplasia in 52 (15%), tumor in 23 (7%), Dandy-Walker malformation in 28 (8%), posterior fossa cyst in 20 (6%), meningitis in 12 (3%), aqueductal stenosis in 4 (1%), and other in 32 (9%). Communicating hydrocephalus was diagnosed in 182 cases (52%), whereas noncommunicating hydrocephalus was present in 156 (44%). Shunt types included 326 ventriculoperitoneal (92%), 17 ventriculopleural (5%), and 10 ventriculoatrial (3%).
One hundred forty-five shunts (41%) were placed with AIS catheters in the 18 months after October 2002, whereas 208 shunts (59%) were placed with non-AIS catheters in the 18 months prior to October 2002. The patient cohort receiving AIS catheters were younger, more frequently premature, had a greater incidence of intracranial hemorrhage as the origin of hydrocephalus, and more frequently had programmable valves (Table 1) . Otherwise, there were no significant differences in patient demographics, origin or type of hydrocephalus, or shunt configuration between the two treatment groups. 
Shunt Infection
There were significantly fewer shunt infections in the patients who had received AIS catheters. Only two patients (1.4%) with AIS catheters experienced shunt infection within the 12-month follow-up period, whereas 25 patients (12%) with non-AIS catheters experienced shunt infection (p Ͻ 0.01). After adjusting for intercohort differences with regard to a primary placement procedure compared with a shunt revision, patient prematurity, and posthemorrhagic hydrocephalus on multivariate analysis, AIS catheters were independently associated with a 2.4-fold decreased likelihood of shunt infection (relative risk = 0.41, 95% confidence interval 0.32-0.52, p Ͻ 0.01).
Further evaluation of the medical treatment provided to the patients with shunt infections revealed that patients with infections in standard shunt components had more factors associated with medical costs than those with AIS infections. Specifically, infected patients with standard shunt components experienced a longer average hospital stay (30 days compared with 17 days) and more inpatient complications related to infection treatment, and a greater percentage of these patients had multiple organism infections and multiple antibiotic regimens (Table 2) .
DISCUSSION
The majority of CSF shunt infections appear within the first 6 months postinsertion and likely result from direct inoculation of shunt components by nonpathogenic skin flora at the time of surgery. 5, 7, 8, 10, 12 Antibiotic-impregnated shunt systems have been developed to decrease progression of colonization to infection, and in a small number of studies the introduction of an AIS system in a hydrocephalic patient population has been shown to decrease the incidence of early shunt infections. 9, 13 Skepticism remains concerning the efficacy of such shunt components, however. Moreover, the use of more expensive AIS components to treat pediatric hydrocephalus can increase medical costs.
In the present study, pediatric patients with hydrocephalus were treated using CSF shunts with either standard or AIS components. The patient populations were very similar to each other and differed significantly only in age, origin of hydrocephalus, and type of shunt valve (Table 1) . According to results of multivariate analysis, there were significantly fewer infections in patients with the AIS systems compared with those who had received standard components. In addition, a review of the treatments for these shunt infections revealed fewer factors associated with increased medical costs in patients with AIS components than in those with standard components. Specifically, patients with AIS components that became infected had a shorter average hospital stay and fewer inpatient complications related to infection treatment, and a smaller percentage of these patients had multiple organism infections and multiple antibiotic regimens.
Although the true cost of using AIS components as opposed to standard ones will not be borne out until the actual medical costs are tabulated in our patient population, the preliminary evaluation of such factors may provide insights into the actual costs of adding AIS components to the neurosurgical armamentarium. First, decreasing the overall incidence of infection will undoubtedly contribute to lowering costs. Second, even in cases in which AIS catheters became infected, the patients were less likely to be contaminated with multiple organisms and antibioticresistant organisms. Treatment of these polymicrobial infections often involves the use of multiple antibiotics. Such broad coverage may lead to increased costs not only directly but also indirectly, given that the chance for antibiotic-associated morbidities (drug toxicity, development of antibiotic resistance, need for central venous access for drug delivery, and so forth) may increase. This assumption may partially explain the increased complications noted in the infected patients with standard shunt components (Table 2) .
Third, although a long-term cost-lowering benefit of using AIS components may never be accurately calculated, it is worth entertaining the possibility that a smaller incidence of shunt infections coupled with the occurrence of less severe infections, as was demonstrated in the present study, will ultimately lower the overall long-term morbidity associated with shunt infection. Such morbiditiesincluding psychomotor retardation, persistent seizure disorders, and permanent, dependent disability-likely have far greater costs to society than the inpatient hospital costs, both financially and otherwise.
CONCLUSIONS
In this study, factors associated with increased medical costs were greater in pediatric patients with infected CSF shunts when the shunt components were standard as opposed to antibiotic-impregnated. The exact calculation of the medical costs incurred while treating these CSF shunt infections is currently underway and may provide a more accurate assessment of the cost effectiveness, or the lack thereof, of using AIS components to treat hydrocephalus.
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